Adagio Therapeutics, Inc. (ADGI) |
|
4.64 0.04 (0.87%)
|
09-13 00:00 |
|
Open: |
4.62 |
Pre. Close: |
4.6 |
|
High:
|
4.74 |
Low:
|
4.4 |
|
Volume:
|
534,999 |
Market Cap:
|
506(M) |
|
|
|
Technical analysis |
as of: 2022-11-18 4:18:23 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 5.53 One year: 6.46 |
| Support: |
Support1: 3.74 Support2: 3.13 |
| Resistance: |
Resistance1: 4.73 Resistance2: 5.53 |
| Pivot: |
4.59 |
| Moving Average: |
MA(5): 4.63 MA(20): 4.39
MA(100): 3.97 MA(250): 6.23  |
| MACD: |
MACD(12,26): 0.2 Signal(9): 0.2 |
| Stochastic oscillator: |
%K(14,3): 89.7 %D(3): 90.1 |
| RSI: |
RSI(14): 70.7 |
| 52-week: |
High: 78.81 Low: 2.41 |
| Average Vol(K): |
3-Month: 401 (K) 10-Days: 535 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ADGI ] has closed below upper band by 43.3%. Bollinger Bands are 41.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.74 - 4.77 |
4.77 - 4.79 |
|
Low:
|
4.35 - 4.37 |
4.37 - 4.39 |
|
Close:
|
4.6 - 4.64 |
4.64 - 4.68 |
|
Company Description |
|
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts. |
Headline News |
Thu, 10 Aug 2023
INVIVYD INVESTIGATION INITIATED BY FORMER LOUISIANA ... - GlobeNewswire
Tue, 28 Feb 2023
INVIVYD SHAREHOLDER ALERT: CLAIMSFILER REMINDS ... - GlobeNewswire
Mon, 12 Sep 2022
Adagio Therapeutics Announces Corporate Name Change to Invivyd - Yahoo Finance
Tue, 05 Jul 2022
Mithril Capital's Ajay Royan Sends Letter Thanking Adagio ... - Business Wire
Thu, 06 Jan 2022
U.S. RESEARCH ROUNDUP Akamai Technologies, Gitlab, RPM ... - Reuters.com
Wed, 15 Dec 2021
Top 5 IPOs of 2021 - Investopedia
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
111 (M) |
| Shares Float |
48 (M) |
|
% Held by Insiders
|
32.5 (%) |
|
% Held by Institutions
|
67.1 (%) |
|
Shares Short
|
3,920 (K) |
|
Shares Short P.Month
|
4,380 (K) |
Stock Financials |
|
EPS
|
-14.74 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
5.69 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-220 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-0.32 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.81 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-2.35 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
